Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Successful clinical outcomes for late-stage ADC candidates and continued label expansions for current assets fully offset the 2028 Keytruda loss of exclusivity.
Severe Keytruda Cliff: Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverage M&A to offset the massive patent cliff approaching in 2028.
Intangible Assets (Patents)
Economies of Scale
Accelerating M&A and robust pipeline readouts across the biopharma sector.
Hold. Valuation balances near-term strength against back-half transition risks.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenue and M&A integration issues, compressing gross margins.
Intangible Assets (Patents)
Economies of Scale
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $21.2B after capex $4.1B, with terminal value at 69.7% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If ADC readouts are positive, re-rate terminal multiple. If negative, shift focus to capital allocation and dividend safety.
If ADC readouts are positive, re-rate terminal multiple. If negative, shift focus to capital allocation and dividend safety.
If ADC readouts are positive, re-rate terminal multiple. If negative, shift focus to and dividend safety.
Heavy reinvestment phase focusing on acquisitions and R&D to replace expiring revenue streams.
Accelerating M&A and robust pipeline readouts across the biopharma sector.
Patent cliffs across major blockbuster drugs driving sector-wide PE compression.
Heavy reinvestment phase focusing on acquisitions and R&D to replace expiring revenue streams.
Hold. Consider as a mature dividend-payer core holding with high dependence on pipeline replacement.
Trim if the stock consistently exceeds the $146.75 bull target without accompanying pipeline upgrades.
Hold.
The $120.61 fair value synthesis balances near-term operational momentum against the severe structural hurdle of the 2028 Keytruda LOE.
Hold.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Pipeline failures, aggressive pricing competition post-Keytruda exclusivity, and IRA regulatory pressures compress margins and stall revenue growth, significantly endangering the long-term dividend growth rate and compressing terminal multiples.
Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.
Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.
The five developments that would weaken our investment case.
Premature top-line stagnation ahead of the major patent cliff would expose the business to severe revenue replacement shortfalls, accelerating terminal valuation multiple compression.
Current:1.3% for the period ended 2025-12-31
Alert ifcontracts below 0.0% over any trailing twelve-month period
Regulatory rejections or clinical trial terminations for key pipeline candidates would destroy R&D capital efficiency and eliminate critical revenue diversification needed to offset future patent expiries.
Current:17.4% as of the report's 2026-05-08 analysis date
Alert iffalls below 12.0% across any annual reporting period
Unproductive research spending that fails to yield commercially viable therapies would dilute corporate profitability, depressing operating cash flows and eroding overall return on invested capital.
Current:34.0% for the period ended 2025-12-31
Alert ifdrops below 28.0% over any four-quarter period
Unfavorable shift in pharmaceutical product mix and pricing erosion from mandatory government discounting would squeeze gross margins, narrowing the funding cushion needed for clinical trials and strategic investments.
Current:74.8% for the period ended 2025-12-31
Alert ifdeclines below 70.0% in any fiscal year
Deteriorating operating cash generation relative to reported net income would constrain capital allocation flexibility, pressuring shareholder payouts and forcing greater reliance on external debt financing.
Current:0.902 as of the report's 2026-05-08 analysis date
Alert iffalls below 0.750 over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Successful clinical outcomes for late-stage ADC candidates and continued label expansions for current assets fully offset the 2028 Keytruda loss of exclusivity. This drives steady single-digit revenue growth and supports continued dividend expansion.
Near-term operational momentum remains strong, but long-term cash flows are penalized to account for the impending revenue concentration cliff. A balanced approach weighting near-term execution against the inevitable 2028 strategic transition.
If ADC readouts are positive, re-rate terminal multiple. If negative, shift focus to capital allocation and dividend safety.
Warning level: contracts below 0.0% over any trailing twelve-month period. Premature top-line stagnation ahead of the major patent cliff would expose the business to severe revenue replacement shortfalls, accelerating terminal valuation multiple compression.
Warning level: falls below 12.0% across any annual reporting period. Regulatory rejections or clinical trial terminations for key pipeline candidates would destroy R&D capital efficiency and eliminate critical revenue diversification needed to offset future patent expiries.
Warning level: drops below 28.0% over any four-quarter period. Unproductive research spending that fails to yield commercially viable therapies would dilute corporate profitability, depressing operating cash flows and eroding overall return on invested capital.
Warning level: declines below 70.0% in any fiscal year. Unfavorable shift in pharmaceutical product mix and pricing erosion from mandatory government discounting would squeeze gross margins, narrowing the funding cushion needed for clinical trials and strategic investments.
Warning level: falls below 0.750 over any trailing twelve-month period. Deteriorating operating cash generation relative to reported net income would constrain capital allocation flexibility, pressuring shareholder payouts and forcing greater reliance on external debt financing.
| $60.12B |
| $64.17B |
| $65.01B |
| +3.1% |
| Gross profit | $41.87B | $43.99B | $48.98B | $48.63B | +5.1% |
| Operating income | $17.41B | $3.04B | $21.21B | $22.42B | +8.8% |
| Net income | $14.52B | $365.0M | $17.12B | $18.25B | +7.9% |
| EPS (diluted) | $5.71 | $0.14 | $6.74 | $7.28 | +8.4% |
| EBITDA | $21.32B | $6.91B | $25.71B | $28.26B | +9.9% |
| R&D | $13.55B | $30.53B | $17.94B | $15.79B | +5.2% |
| SG&A | $10.04B | $10.50B | $10.82B | $10.73B | +2.2% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 65,011,000,000 |
|---|---|
| Cost of revenue | 16,382,000,000 |
| Gross profit | 48,629,000,000 |
| Operating expenses | 26,522,000,000 |
| Operating income | 22,107,000,000 |
| Non-operating items and tax | -3,853,000,000 |
| Net income | 18,254,000,000 |
| Total assets | 136,866,000,000 |
|---|---|
| Cash | 14,565,000,000 |
| Current assets | 43,516,000,000 |
| Total liabilities | 84,204,000,000 |
| Current liabilities | 28,327,000,000 |
| Shareholders’ equity | 52,606,000,000 |
Point-in-time financial data used in the 2026-05-08 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | 14.1B | 9.7B | 4.4B | 3.2B | 479M | 840M | 6.6B | 1.6B | — | — | — | — | — | — | — | — | — | — |
| 2022-12-31 | 59.3B | 21.3B | 14.5B | 19.1B | 14.7B | 4.4B | 3.9B | 541M | 0 | 7B | -2.3B | — | — | — | — | 12.7B | 30.7B | 30.8% | — | 6.5% | — |
| 2023-12-31 | 60.1B | 6.9B | 365M | 13B | 9.1B | 3.9B | 3.9B | 645M | 1.3B | 7.4B | 4.2B | — | — | — | — | 6.8B | 35.1B | 4.9% | — | 6.1% | — |
| 2024-12-31 | 64.2B | 25.7B | 17.1B | 21.5B | 18.1B | 3.4B | 4.5B | 761M | 1.3B | 7.8B | 2.3B | — | — | — | — | 13.2B | 37.1B | 31.5% | — | 7.0% | — |
| 2025-12-31 | 65B | 28.3B | 18.3B | 16.5B | 12.4B | 4.1B | 5.8B | 820M | 5.1B | 8.2B | 11.4B | — | — | — | — | 14.6B | 49.3B | 34.0% | — | 6.4% | — |
MRK trades at 11.8x forward earnings against a peer median of 14.0x; EV/EBITDA of 10.9x against a peer median of 14.1x; 6 peers.
| Level | Action |
|---|
| Thesis break | Trim if the stock consistently exceeds the $146.75 bull target without accompanying pipeline upgrades. |
| Johnson & Johnson |
| 17.5x |
| 5.6x |
| 16.6x |
| 26.4% |
| 27.4% |
| ABBV | AbbVie Inc. | 12.5x | 5.7x | 14.1x | 62.2% | 31.6% |
| AMGN | Amgen Inc. | 14.0x | 4.8x | 13.2x | 101.3% | 33.8% |
| GILD | Gilead Sciences Inc. | 13.9x | 5.7x | 12.5x | 40.7% | 37.4% |
